journal article·2018-04-03Open access

MicroRNA-221-3p is up-regulated and serves as a potential biomarker in pancreatic cancer

Feng Li, Jian-Wei Xu, Lei Wang, Han Liu, Ye Yan, San-Yuan Hu

Abstract

It has been demonstrated that circulating MicroRNAs (miRNAs) could be potential biomarkers for cancer diagnosis and prognosis. For pancreatic cancer (PCa), little is known about miR-221-3p biological function or its prognostic value. In the current study, we profiled miR-221-3p expression in PCa cell lines. Compared with normal pancreases ductal epithelial cells, miR-221-3p is up-regulated in all PCa cell lines analysed. In SW1990 cells, overexpression of miR-221-3p increased cell proliferation and inhibited apoptosis, while inhibition of miR-221-3p decreased cell growth rate and promoted apoptosis. Compared with adjacent non-tumour tissues, miR-221-3p was up-regulated in all 21 PCa tissues. Expression level of miR-221-3p was investigated in plasma and statistical analyses showed that circulating miR-221-3p expression level was correlated with distant metastasis and TNM stages. The receiver-operating characteristic (ROC) curves and the area under the ROC curve (AUC) suggested that the diagnostic efficacy for distant metastasis of miR-221-3p is better than CA19-9 (AUC: 0.689 vs. 0.587). To summary, we found miR-221-3p could promote cell proliferation and inhibit apoptosis in PCa cells and circulating miR-221-3p could serve as a biomarker for PCa.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Cancer-related molecular mechanisms research · Circular RNAs in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China;

Departments of Ultrasound and Radiology, Provincial Hospital Affiliated to Shandong University, Jinan, China

References (32)

Show source-provided references
1. 10.3322/caac.2120810.3322/caac.21208 ↗
2. 10.1016/S0140-6736(10)62307-010.1016/S0140-6736(10)62307-0 ↗
3. 10.1200/JCO.2011.36.574210.1200/JCO.2011.36.5742 ↗
4. 10.1002/jso.293029010610.1002/jso.2930290106 ↗
5. 10.1002/cncr.2773410.1002/cncr.27734 ↗
6. 10.1016/j.pan.2012.11.31310.1016/j.pan.2012.11.313 ↗
7. 10.1016/j.cell.2009.01.00210.1016/j.cell.2009.01.002 ↗
8. 10.1038/nrg307410.1038/nrg3074 ↗
9. 10.1038/nrc393210.1038/nrc3932 ↗
10. Song S · Nat Rev · 2013 · 10 · 109
11. 10.1200/JCO.2009.24.934210.1200/JCO.2009.24.9342 ↗
12. 10.1073/pnas.101905510810.1073/pnas.1019055108 ↗
13. 10.1038/ncb221010.1038/ncb2210 ↗
14. 10.1074/jbc.M110.10782110.1074/jbc.M110.107821 ↗
15. Yu X · Ann Transl Med · 2015 · 3 · 297
16. 10.1371/journal.pone.009284710.1371/journal.pone.0092847 ↗
17. 10.1210/jc.2013-162910.1210/jc.2013-1629 ↗
18. 10.1016/j.atherosclerosis.2015.06.03110.1016/j.atherosclerosis.2015.06.031 ↗
19. 10.1016/j.gene.2014.11.03610.1016/j.gene.2014.11.036 ↗
20. 10.1016/j.bbrc.2017.01.00210.1016/j.bbrc.2017.01.002 ↗
21. 10.1016/j.bbrc.2017.01.00210.1016/j.bbrc.2017.01.002 ↗
22. 10.3727/096504016X1475628281938510.3727/096504016X14756282819385 ↗
23. 10.1016/j.gene.2016.06.05910.1016/j.gene.2016.06.059 ↗
24. 10.18632/oncotarget.895310.18632/oncotarget.8953 ↗
25. 10.1042/bse054012710.1042/bse0540127 ↗
26. 10.18632/oncotarget.765110.18632/oncotarget.7651 ↗
27. 10.1002/cam4.62610.1002/cam4.626 ↗
28. 10.1111/cas.1290410.1111/cas.12904 ↗
29. 10.1007/s13277-016-5445-810.1007/s13277-016-5445-8 ↗
30. 10.18632/oncotarget.1176810.18632/oncotarget.11768 ↗
31. 10.1038/bjc.2015.36610.1038/bjc.2015.366 ↗
32. 10.3892/ijo.2014.274310.3892/ijo.2014.2743 ↗